Arcus Biosciences (NYSE:RCUS) CAO Sells $51,986.88 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,376 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $51,986.88. Following the completion of the sale, the chief accounting officer owned 24,987 shares in the company, valued at $546,715.56. The trade was a 8.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alexander Azoy also recently made the following trade(s):

• On Thursday, December 18th, Alexander Azoy sold 4,343 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.25, for a total transaction of $96,631.75.
• On Wednesday, December 17th, Alexander Azoy sold 2,113 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.16, for a total transaction of $46,824.08.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The stock was sold at an average price of $26.00, for a total transaction of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The stock was sold at an average price of $13.00, for a total transaction of $36,803.00.

Arcus Biosciences Trading Down 1.2%

RCUS stock traded down $0.26 during midday trading on Thursday, hitting $22.02. The stock had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75. The business has a fifty day moving average price of $20.82 and a two-hundred day moving average price of $13.98. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $26.40.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The firm had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business’s revenue was down 45.8% compared to the same quarter last year. During the same period last year, the business posted ($1.00) EPS. On average, sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

Large investors have recently modified their holdings of the company. Amalgamated Bank raised its holdings in shares of Arcus Biosciences by 3.9% in the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $266,000 after purchasing an additional 736 shares during the last quarter. Creative Planning boosted its holdings in Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after purchasing an additional 771 shares during the last quarter. GAMMA Investing LLC grew its position in Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after purchasing an additional 1,021 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Arcus Biosciences by 8.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock worth $142,000 after purchasing an additional 1,294 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in Arcus Biosciences by 1.6% in the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock valued at $716,000 after buying an additional 1,422 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on RCUS. Wedbush set a $35.00 target price on Arcus Biosciences and gave the stock an “outperform” rating in a report on Wednesday, October 29th. HC Wainwright raised their price objective on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group increased their target price on shares of Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.